Edition:
United States

Profile: Viking Therapeutics Inc (VKTX.PH)

VKTX.PH on Philadelphia Stock Exchange

6.97USD
10:30am EDT
Change (% chg)

$0.06 (+0.87%)
Prev Close
$6.91
Open
$6.94
Day's High
$6.97
Day's Low
$6.94
Volume
200
Avg. Vol
5,549
52-wk High
$24.00
52-wk Low
$6.56

Viking Therapeutics, Inc., incorporated on October 24, 2012, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). The Company's second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. VK2809 belongs to a family of prodrugs, which are cleaved in vivo to release potent thyromimetics. The Company is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). X-ALD is an X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The disease is caused by mutations in a peroxisomal transporter of very long chain fatty acids (VLCFA), known as the adenosine triphosphate binding cassette transporter D1, or ABCD1.

The Company has a pipeline with approximately three additional programs targeting metabolic diseases and anemia. Its advanced pipeline program is VK0612, an orally available Phase IIb-ready drug candidate for type II diabetes. The Company's preclinical programs are focused on identifying orally available erythropoietin receptor, or EPOR, agonists, for the treatment of anemia, and on the development of tissue-selective inhibitors of diacylglycerol acyltransferase-1, or DGAT-1, for the treatment of obesity and dyslipidemia.

The Company competes with Novartis AG, Morphosys AG, GTx, Inc., Helsinn Group, Merck & Co., Intercept Pharmaceuticals, Inc., Genfit SA, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., Conatus Pharmaceuticals Inc., MedDay Pharmaceuticals SAS, bluebird bio, Inc., Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited and TransTech Pharma, Inc.

Company Address

Viking Therapeutics Inc

12340 El Camino Real Ste 250
SAN DIEGO   CA   92130-3093
P: +1858.7044660
F: +1302.6365454

Company Web Links